TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Public ClinicalTrials.gov record NCT04485013. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination With Pembrolizumab, Cetuximab or FOLFIRI Plus Cetuximab in Patients With Advanced Solid Refractory/Resistant Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.
Study identification
- NCT ID
- NCT04485013
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 240 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 14, 2020 (Actual)
- Primary completion
- Jun 1, 2027 (Estimated)
- Completion
- Jun 1, 2027 (Estimated)
- Last update posted
- Sep 11, 2026
2020 – 2027
United States locations
- U.S. sites
- 41
- U.S. states
- 26
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates | Tucson | Arizona | 85711 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| Hoag Memorial Hospital | Newport Beach | California | 92663 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Yale Cancer Center | New Haven | Connecticut | 06511 | — |
| Christiana Care Helen F. Graham Cancer Center | Newark | Delaware | 19713 | — |
| John Hopkins Kimmer Cancer Center | Washington D.C. | District of Columbia | 20016 | — |
| Florida Cancer Specialists | Daytona Beach | Florida | 32117 | — |
| Florida Cancer Specialists | Fleming Island | Florida | 32003 | — |
| Ocala Oncology Center | Ocala | Florida | 34474 | — |
| AdventHealth Research Institute | Orlando | Florida | 32804 | — |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | — |
| University of Illinois | Chicago | Illinois | 60612 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40241 | — |
| American Oncology Partners, P.A. - The Center for Cancer & Blood Disorders | Bethesda | Maryland | 20817 | — |
| Maryland Oncology Hematology | Silver Spring | Maryland | 20904 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| START Midwest | Grand Rapids | Michigan | 49546 | — |
| Regions Hospital Cancer Care Center | Saint Paul | Minnesota | 55101 | — |
| Washington University in St Louis | St Louis | Missouri | 63110 | — |
| Nebraska Cancer Center Oncology Hematology West P.C. | Omaha | Nebraska | 68130 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Stony Brook University | Stony Brook | New York | 11794 | — |
| University of Cincinnati | Cincinnati | Ohio | 45267 | — |
| Zangmeister Cancer Center | Columbus | Ohio | 43219 | — |
| The University of Toledo | Toledo | Ohio | 43606 | — |
| University of Oklahoma | Oklahoma City | Oklahoma | 73104 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Vanderbilt - Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Texas Oncology - Dallas | Dallas | Texas | 75246 | — |
| START Dallas | Fort Worth | Texas | 76104 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology - Paris | Paris | Texas | 75460 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
| NEXT Oncology Virginia | Fairfax | Virginia | 22031 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
| Northwest Cancer Specialists | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04485013, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04485013 live on ClinicalTrials.gov.